Published August 27, 2026 · updated August 27, 2026 · regulatory and clinical facts last checked 2026-08-27 · medically reviewed by Dr. S. Shuwart, MD on August 27, 2026

Medically reviewed · August 27, 2026

Semaglutide base vs sodium and acetate salts

What FDA has said about compounded products made with semaglutide sodium or semaglutide acetate, why the salt form matters, and how to find out which form a provider's pharmacy uses.

What FDA said

FDA’s consumer and provider communication on semaglutide states that the agency received reports of compounders using semaglutide sodium and semaglutide acetate, that these salt forms are not the active ingredient in the approved products, and that it was not aware of any basis for compounding a drug using the salt forms. It also noted that the salt forms do not appear on the lists of bulk drug substances that may be used in compounding and that the approved products use semaglutide base.

Why it matters

Beyond the regulatory point, a different salt can behave differently in solution and in the body, and no trial has examined a compounded semaglutide salt preparation. The question is therefore not “which is better” but “is this the substance the approved product uses, and does the pharmacy know.”

How to find out

Ask the provider, in writing, which pharmacy compounds its semaglutide and whether the active ingredient is semaglutide base. Some pharmacies publish certificates of analysis for their active ingredient on request; a provider that can produce one has answered fully. This site records for each provider whether the form is disclosed; see the Compounding Disclosure Index.

What we do not say

We do not say that any specific provider or pharmacy uses a salt form unless we have a source, and we do not say that a compounded base preparation is equivalent to the approved product; it is not FDA-approved and has not been tested.

Questions this page answers

Does a salt form work the same?
There is no published evidence on the clinical performance of compounded semaglutide salt preparations. The regulatory point is that they are different substances from the approved active ingredient and do not meet the conditions for compounding; the clinical point is that nobody has tested them.

Sources

  1. FDA: Medications containing semaglutide marketed for type 2 diabetes or weight loss (regulator)
  2. Ozempic and Wegovy prescribing information (description sections) (label)

Related: /guides/tirzepatide-base-vs-salt/ /guides/wegovy-vs-compounded-semaglutide/ /guides/compounded-semaglutide-legal-status/

Educational information, not medical advice. Decisions about GLP-1 medication belong with you and a licensed clinician who knows your history. Compounded medications are not FDA-approved. Report an error.